Table 1 Demographic and MS-related characteristics of participants
Characteristic | N (%) |
|---|---|
Females | 35 (70) |
Age (mean, range) | 44.4 (21–61) |
Highest professional qualification | |
Still in vocational training | 1 (2) |
No professional qualification | 2 (4) |
Vocational education | 27 (54) |
Bachelor’s degree | 4 (8) |
Master’s degree, Diploma, state examination | 14 (28) |
Doctorate | 2 (4) |
MS type | |
RRMS | 44 (88) |
SPMS | 6 (12) |
Years with MS since diagnosis (mean, range) | 13.4 (2–33) |
Patient determined disease steps (PDDS) (mean, range) | 2.7 (0–7) |
Current DMT use | 39 (78) |
Number of different DMT use so far | |
0 | 3 (6) |
1 | 3 (6) |
2 | 11 (22) |
3 | 13 (26) |
4 | 12 (24) |
> 5 | 8 (16) |
Experience with DMTs | |
Glatiramer acetate | 16 (32) |
Interferon-beta | 33 (66) |
Dimethyl fumarate | 15 (30) |
Teriflunomid | 10 (20) |
Alemtuzumab | 7 (14) |
Daclizumab | 4 (8) |
Fingolimode | 17 (34) |
Natalizumab | 17 (34) |
Cladribine | 3 (6) |
Ocrelizumab | 8 (16) |
Mitoxantrone | 3 (6) |